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ABSTRACT OF THE DISSERTATION

EVALUATION OF THE SURVIVAL EFFECT FOR VARIOUS TREATMENT
MODALITIES AMONG STAGE II AND III RECTAL CANCER PATIENTS
IN CALIFORNIA, 1994-2009
by
Myung Mi Cho, MD
Doctor of Public Health Candidate in Epidemiology
Loma Linda University, 2012
Raymond Knutsen, MD, MPH, Chair

Background: European trials evaluating the effect of preoperative (PreOP) versus
postoperative chemoradiotherapy (PostOP CRT) found no survival benefit. However, the
effect of a change from PostOP to PreOP CRT has not been evaluated in a populationbased setting. We sought to evaluate multimodal treatment changes and overall survival
for perioperative (PeriOP) CRT versus surgery alone and for PreOP versus PostOP CRT
from 1994 through 2009 among patients receiving radical surgery for stage II and III
rectal cancer (RC).
Patients and Methods: We conducted a nonconcurrent cohort study evaluating
demographic predictors of multimodal therapy for stage II and III RC using the diverse
California Cancer Registry population-based data. First, we compared patients who
received only surgery versus those receiving surgery plus PeriOP CRT. Second, we
compared patients who received PreOP CRT with those receiving PostOP CRT. Cox
proportional hazards regression was used to assess survival over 192 months in both

m

study groups, adjusting for date of surgery, stage, age, gender, race/ethnicity, and
socioeconomic status (SES).
Results: The Cox proportional hazards regression analysis showed that PeriOP
CRT was associated with lower mortality, and the hazards ratio (HR) decreased with each
time period (1994-1997: HR=0.73, 0.65-0.83; 1998-2001: HR=0.66,0.60-0.73; 20022005: HR=0.55, 0.49-0.61; and 2006-2009: HR=0.36, 0.31-0.43) (ptrend<0.0001). For

PreOP versus PostOP CRT, our findings showed a stepwise increase (OR, 95% Cl) in the
use of PreOP CRT across three time-periods (1994-1997: OR=0.07, 0.06-0.08; 19982005: OR=0.33, 0.29-0.36; 2006-2009: OR=l) which was concomitant with publication
of findings from European trials. However, we did not find a clear survival benefit for
PreOP versus PostOP CRT.
Conclusions: Younger age-groups were more likely to receive PeriOP and PreOP
CRT. The same was true for males compared to females. Survival was significantly better
among patients receiving PeriOP CRT versus surgery alone, and the survival benefit
increased over the time-period of our study, suggesting CRT procedures have been
modified over time. Our study identified a clear shift in timing of PeriOP CRT from
PostOP to PreOP. However, we found no clear support for a survival benefit associated
with this shift. Our findings are in line with the results from clinical trials.
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CHAPTER 1
INTRODUCTION

A. Statement of the Problem
In 2012, an estimated 40,290 new rectal cancer (RC) cases will be diagnosed
among Americans (Siegel, Naishadham, & Jemal, 2012), while the estimate is 4,235 new
diagnoses and 935 deaths for California (California Cancer Facts & Figures 2012).
During the 1990’s, the United States National Institutes of Health Consensus Conference
(NIH Consensus Conference, 1990) and the German Cancer Society Consensus
Conference (Junginger, Hossfeld, Sauer, & Hermanek, 1999) recommended the use of
postoperative (PostOP) chemoradiotherapy (CRT) for Stage II and III RC. However,
current National Comprehensive Cancer Network (NCCN) guidelines (National
Comprehensive Cancer Network, 2012) recommend a series of multimodality therapies
which consist of preoperative (PreOP) radiation therapy (RT) with concurrent
chemotherapy, transabdominal resection, and PostOP chemotherapy within six months
for stage II and III RC. These recommendations resulted from reports from several
European trials during the last twenty years, particularly a Swedish rectal cancer trial
(Swedish Rectal Cancer Trial, 1997) and a German rectal cancer study (Sauer, Becker, &
Hohengerger, 2004).
B. Purpose of the Study
While it is reasonable to assume that outcome improvements along with current
NCCN guidelines (National Comprehensive Cancer Network, 2012) have prompted
changes in the treatment of stage II and III RC, survival benefits of these changes have
not been adequately tested in a large-scale population-based setting. Thus, we sought to
1

conduct a non-concurrent cohort study to evaluate survival benefits of perioperative
(PeriOP, PreOP and/or PostOP) CRT versus surgery alone and PreOP CRT versus
PostOP CRT, adjusting for age, gender, race/ethnicity, and socioeconomic status (SES),
from 1994 through 2009 among patients receiving radical operations for stage II and III
RC using the diverse California population.
C. Hypotheses
L Perioperative Chemoradiotherapy Versus Surgery Alone
a. Null hypothesis: There is no difference in survival between
perioperative chemoradiotherapy (PeriOP CRT) and surgery alone among patients
receiving radical surgery for stage II and III RC.
b. Alternative hypothesis: PeriOP CRT is associated with better survival
than surgery alone among patients receiving radical surgery for stage II and III RC.
2. Preoperative Chemoradiotherapy Versus Postoperative Chemoradiotherapy
a. Null hypothesis: There is no difference in survival between preoperative
(PreOP) CRT and postoperative (PostOP) CRT among patients receiving radical surgery
for stage II and III RC.
b. Alternative hypothesis: PreOP CRT is associated with better survival
than PostOP CRT among patients receiving radical surgery for stage II and III
RC.
D. Research Questions
1. Perioperative Chemoradiotherapy Versus Surgery Alone
Two Research Questions are addressed:
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a. What factors are associated with receiving perioperative
chemoradiotherapy (PeriOP CRT) compared to surgery alone among stage II and III RC
patients, adjusting for age, gender, race/ethnicity and socioeconomic status (SES)?
b. Is there a survival difference for PeriOP CRT versus surgery alone
among stage II and III RC patients, adjusting for date of surgery, age, gender,
race/ethnicity and SES?
2. Preoperative Chemoradiotherapy Versus Postoperative Chemoradiotherapy
Two research questions are addressed:
a. Are there any changes from postoperative (PostOP) to preoperative
chemoradiotherapy (PreOP CRT) practices among stage II and III RC patients over the
time-period 1994-2009 (i.e., 1994-1997, 1998-2005, and 2006-2009), and by age, gender,
race/ethnicity and SES?
b. Is there a survival difference for PreOP versus PostOP CRT among
stage II and III RC patients, adjusting for date of surgery, age, gender, race/ethnicity and
SES?
E. Significance to Epidemiology
Colorectal cancer (CRC) incidence rates have increased in economically
transitioning countries over the past decade (Center, Jemal, Smith, & Ward, 2009;
Center, Jemal, & Ward, 2009) though, CRC mortality rates have decreased in long
standing developed countries, possibly because of effects of preventive measures like
CRC screening (Center, Jemal, Smith, et ah, 2009; Edwards et ah, 2010). CRC is
currently the third leading cause of cancer deaths among both females and males in the
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United States with a 5-year survival rate of 68% nationally (Siegel, Naishadham, &
Jemal, 2012).
NCCN guidelines (National Comprehensive Cancer Network, 2012) with
standard treatments for cancer are different depending on TNM staging. TNM staging for
colon and RC is defined together; however, there are outcome differences between colon
cancer and RC. For example, the locoregional recurrence is more common for RC than
colon cancer (Rajput & Bullard Dunn, 2007; Weiser et al., 2005; Wiig, Larsen &
Giercksky, 2005), most likely because of the proximity to pelvic structures, absence of
serosa, and technical challenges encountered in obtaining wide surgical margins.
RC incidence and mortality rates differ according to demographic factors like age,
gender, race/ethnicity, and SES. These differences may, at least in part, be explained by
demography associated treatment selections which in turn affect survival. It is, therefore,
of interest to assess any association between demographic variables and multimodality
treatment.
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CHAPTER 2
LITERATURE REVIEW

A. Introduction
In 2008, more than 1.2 million new colorectal cancer (CRC) cases and 608,000
CRC deaths were estimated world-wide (Jemal, Bray, Center, Ferlay, Ward, et ah, 2011).
Incidence rates of CRC vary markedly worldwide, with rates per 100,000 for the 19982002 periods ranging from 3.6 and 4.1 among females and males, respectively, in
Karunagappally, India to 39.5 for females in New Zealand and 59.1 for males in the
Chech Republic (Center, Jemal, Smith, & Ward, 2009). Over the past decade, CRC
incidence rates have been increasing in economically transitioning countries like the
Czech Republic and Slovakia, and in several areas historically at low risk, including
Spain and a number of countries in Eastern Asia and Eastern Europe (Center, Jemal,
Smith, et al., 2009). The incidence rates in males in the Czech Republic and Japan have
already exceeded the peak incidence observed in the United States and other long
standing developed nations like Canada and Australia where rates are stabilizing (Center,
Jemal, Smith, et al., 2009; Center, Jemal, & Ward, 2009). These unfavorable trends are
thought to reflect a combination of factors, including changes in dietary pattern, obesity.
and an increased prevalence of smoking (Center, Jemal, Smith, et al., 2009; Center,
Jemal, & Ward, 2009).
The United States is the only country in which CRC incidence has decreased
significantly among both females and males in recent years, possibly due to favorable
changes in risk factors/lifestyle habits as well as early detection of precancerous lesions
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by CRC screening and removal of these (Center, Jemal, Smith, & Ward, 2009; Edwards
et ah, 2010).
CRC is projected to be the second leading cause of cancer death in the United
States in 2012, ranking number three among both females and males, and producing an
estimated 51,690 deaths (25,220 females and 26,470 males), nationwide. In the same
year, it is estimated that there will be 143,460 (70,040 females and 73,420 males) new
CRC diagnoses of which 40,290 (16,790 females and 23,500 males) are new rectal cancer
(RC) diagnoses among Americans (Siegel, Naishadham, & Jemal, 2012). In California
for 2012, the expected numbers of new CRC cases are 14,530 (7,000 females and 7,530
males), resulting an estimated 5,120 deaths (2,505 females and 2,615 males) (California
Cancer Facts & Figures 2012). Of these, it is estimated that 4,235 will be RC (1,785
females and 2,450 males) and 935 (405 females and 535 males) will die from it
(California Cancer Facts & Figures 2012). With a 66% five-year survival rate, CRC has a
poorer prognosis than breast (91%) and prostate cancers (100%), respectively, in
California (California Cancer Facts & Figures, 2012).
B. Character of Rectal Cancer
1. Anatomy of Rectum
Rectal cancer (RC) originates within 12 cm proximal from the anal verge
(Graff, 2010; Kapiteijn et ah, 2001; Nelson et ah, 2001) on the same level as the superior
rectal valve (he., valves of Houston). The colon and upper one third of the rectum are
covered by serosa (he., intraperitoneal), however, the middle and lower portions of the
rectum lack any serosa (i.e. extraperitoneal) (Koshinski, Habr-Gama, Ludwig, & Perez,
2012). Pelvic recurrence is more common for rectal than colon cancer (Rajput & Bullard

6

Dunn, 2007; Weiser et al., 2005; Wiig, Larsen, & Giercksky, 2005), in part because of
the proximity to pelvic structures, the absence of serosa, and technical challenges
encountered in obtaining wide surgical margins. The Dutch Colorectal Cancer Group
(Kapiteijn et ah, 2001) reported that the risk of recurrence of rectal cancer partly depends
on tumor location relative to the anal verge; local recurrence rates were particularly low
when the tumor was located more than 10.1 cm from the anal verge, and no significant
difference was observed between patients who received radiation therapy (RT) and
surgery, or those who received surgery alone. Thus, treatment for RC depends on
determination of tumor location by rigid sigmoidoscopy (Schoellhammer, Gregorian,
Sarkisyan, & Petrie, 2008).
2. Risk Factors
Dietary and lifestyle factors may play major roles in the etiology of RC.
Studies have indicated that intake of high energy foods (Giovannucci & Goldin, 1997),
red or processed meats (Larsson & Wolk, 2006; Norat et al., 2005), and alcohol (Moskal,
Norat, Ferrari, & Riboli, 2007) are associated with an increased colorectal cancer (CRC)
risk. Higher intake of fruit and vegetables, however, is associated with a moderately
reduced risk (Koushik et al., 2007; Riboli & Norat, 2003). Other studies have indicated
that insulin, iron, and refined sugars are possible risk factors for CRC, while whole
grains, antioxidants, and phytochemicals may be protective, but the evidence is not
conclusive, and further studies are needed (Boyle & Levin, 2008). Some studies have
reported that obesity (Dai, Xu, & Niu, 2007; Larsson & Wolk, 2007; Moghaddam,
Woodward, & Huxley, 2007; Renehan, Tyson, Egger, Heller, & Zwahlen, 2000) and
cigarette smoking (Liang, Chen, & Giovannucci, 2009; Luchtenborg, White, Wilkens,

7

Kolonel, & Le Marchand, 2007; Morrison et al., 2011) are associated with increased
CRC risk, while both long term use and in higher doses of NS AIDS (non-steroidal anti
inflammatory drugs), particularly aspirin, may be associated with reduced CRC risk
(Chan et ah, 2005; Flossmann & Rothwell, 2007; Jacobs et al., 2007; Larsson,
Giovannucci, & Wolk, 2006). However, the use of NS AIDS for patients with high CRC
risk, such as familial adenomatous polyposis (FAP), requires supervision and close
follow-up by physicians because of possible serious side effects. Current smoking has
been found to increase the risk of colon cancer mortality by 50% and the risk of rectal
cancer mortality by 100%, compared to never smoking (Liang, Chen, & Giovannucci,
2009; Morrison et al., 2011). The use of hormone replacement therapy (HRT) among
females also is associated with reduced risk of CRC, but the risks of breast cancer and
coronary heart disease are increased concomitantly (Boyle & Levin, 2008). Complex
interactions between genetic, dietary, and environmental factors may modify CRC risk as
well (Boyle & Levin, 2008).
3. TNM Stagingfor Rectal Cancer
According to the American Joint Committee on Cancer (AJCC) Cancer
Staging Manual, 7th edition (Edge et al., 2010), the TNM staging system for colorectal
cancer (Stage 0-IV) is based on the depth of primary tumor invasion through the wall (Tis
and Tl-4), the number of regional lymph nodes involved (NO-2), and the absence or
presence of distant metastasis (M0-1). The depth of primary tumor invasion (T) is defined
as carcinoma in situ (i.e., intraepithelial or invasion of lamina propria; Tis), invasion of
submucosa (Tl), invasion of muscularis propria (T2), invasion through the muscularis
propria into the pericolorectal tissue (T3), and penetration to the surface of the visceral
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peritoneum (T4). Involvement of regional lymph nodes (N) is classified as no regional
lymph node metastasis (NO), metastasis in one to three regional lymph nodes (Nl), and
metastasis in four or more regional lymph nodes (N2). Distant metastasis (M) is classified
as no distant metastasis (MO) and distant metastasis (Ml) (Edge et ah, 2010). Thus, stage
0 is TisNOMO, stage I is T1 or T2N0M0, stage II is T3 or T4N0M0, stage III is T(any)Nl
or N2M0, and stage IV is T(any)N(any)Ml.
TNM staging for colon and rectal cancer (RC) are defined together which may
pose a problem because of their outcome differences, such as the risk of local recurrence
which is more common for rectal than colon cancer (Rajput & Bullard Dunn, 2007;
Weiser et ah, 2005; Wiig, Larsen, & Giercksky, 2005). Radiation therapy (RT) is applied
to reduce local recurrence of RC, not of colon cancer. Thus, TNM staging for RC should
be evaluated separately from colon cancer (Koshinski, Habr-Gama, Ludwig, & Perez,
2012).
4. Diagnostic Modalities
Precise preoperative (PreOP) evaluation (i.e., TNM staging) of rectal
cancer (RC) is important in order to plan optimal treatment (Kim, N. K., Kim, M. J., Yun,
Sohn, & Min, 1999). The extent of tumor spread is usually evaluated by endoscopic
ultrasound (EUS), computed tomography (CT), and magnetic resonance imaging (MRI)
(Kim, N. K. et al., 1999; Low et al., 2008). EUS assesses the depth of tumor invasion
through the rectal wall, particularly superficial rectal cancer, and regional lymph node
metastasis (Brown, 2008; Kim, N. K. et al.; Low et al., 2008); one limitation to this
method is the possible over-staging of T2 lesion (Brown, 2008; Low et al., 2008). CT and
MRI are used to detect the presence of distant metastasis (Kim, N. K. et al; Low et al.,
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2008). Although CT has poor spatial and contrast resolution compared to MRI, CT is
more practical and widely available (Low et ah, 2008). Lately, multi-detector CT
(MDCT) has been introduced as a new imaging modality with superior spatial resolution
and a variety of imaging planes to visualize data (Low et al., 2008).
The use of endorectal coils offers high spatial resolution to MRI (Low et al.,
2008). MRI is reliable to detect tumor spread into surrounding organs, particularly to
mesorectal fascia which is a critical structure in total mesorectal excision (TME) for
locally advanced RC (Brown et al., 2003). MRI has limitations compared to EUS due to
over-staging for T1-T2 lesions, and in an attempt to solve this problem, diffusion
weighted MR imaging (DWI) has been tried in a preliminary functional imaging study
(Dzik-Jurasz et al., 2002; Hein et al, 2003).
EUS, CT, and MRI are unreliable in differentiating between lymph node positive
or negative RC (Low et al., 2008). To address the problem, superparamagnetic iron oxide
(SPIO) particles, that is, MRI contrast media, has been proposed to identify
pathophysiological differences between malignant and normal lymph nodes (Low et al.,
2008). SPIO have the property to selectively accumulate in the reticuloendothelial cells
of normal lymph nodes when administered intravenously (Taupitz, Schmitz, & Hamm,
2003). On T2-weighted MRI images, SPIO is not taken up by malignant lymph nodes and
appeared with high signal intensity, while SPIO is taken up by normal lymph nodes and
appeared with low signal intensity (Koh et al., 2004).
C. Surgical Approaches for Rectal Cancer
Surgical resection is still the cornerstone of curative rectal cancer (RC) treatment
method (Kosinski, Habr-Gama, Ludwig, & Perez, 2012). Although there are a variety of
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surgical approaches, treatment of RC depends on the location and extent of the disease
(Guillem & Cohen, 1999; Lindsetmo, Joh, & Delaney, 2008).
Abdominoperineal resection (APR) is the treatment of choice in cases in which
the tumor has invaded the anal sphincter or the levator muscles. APR is en bloc resection
(i.e., the removal of organs in one piece at one time) of the anal canal, the rectum, and the
sigmoid colon, with surrounding mesentery, mesorectum and perianal soft tissue,
followed by permanent end stoma (non-sphincter-preserving) (Marr et al, 2005). Low
anterior resection (LAR, Hartmann’s procedure) is radical proctectomy below the
peritoneal reflection (mid or lower-rectum), sigmoid colectomy with colorectal or
coloanal anastomosis (colon J-pouch or straight anastomosis, sphincter-preserving), or
permanent colostomy (functionally non-sphincter-preserving). Thus, LAR is usually
chosen for lesions in the mid to upper rectum (Kosinski, Habr-Gama, Ludwig, & Perez,
2012). Retrospective studies which compare the treatment outcomes for RC between
APR and LAR reported that LAR has lower local recurrence and better overall survival
rates (den Dulk et al., 2009; Pahlman et al., 2007).
In 1982, total mesorectal excision (TME) was utilized by R. J. Heald as a new
fundamental principle of surgery to reduce local recurrence rates and improve function
after proctectomy (Heald, Husband, & Ryall, 1982). The procedure was introduced
globally in the early 1990’s as the standard surgery for RC (Kapiteijn et al., 2001;
Madsen & Christiansen, 1986; Martijn et al., 2003; Pahlman et al., 2007; Peeters et al.,
2007). The TME approach is designed to radically dissect lymphatic drainage regions of
the tumor above the levator muscles (Schrag, 1996). TME is an en bloc resection of the
mesorectum with surrounding vascular and lymphatic vessels, fatty tissue, and mesorectal
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fascia to spare the autonomic nerves (Baxter & Garcia-Aguilar, 2007; Heald, Husband, &
Ryall, 1982; Lindsetmo, Joh, & Delaney, 2008), and is followed by coloanal anastomosis
if anal function is intact.
D. Multimodal Therapy for Stage II and HI Rectal Cancer
1. Adjuvant (Postoperative) Therapy
Until the mid 1980s, surgical resection without adjuvant therapy was the
method used for locally advanced rectal cancer (RC) (Yorio, Bhadkamkar, Kee, &
Garrett, 2012). However, it carried a high risk of local and distant recurrence (Gunderson
et al., 2004). In 1985, the Gastrointestinal Tumor Study Group (GITSG) (Gastrointestinal
Tumor Study Group, 1985) assessed the recurrence and survival rates of postoperative
chemoradiotherapy (PostOP CRT) for locally advanced RC among four treatment groups
(e.g., surgery alone as control, PostOP radation therapy [RT], PostOP chemotherapy, and
PostOP CRT), and reported that PostOP CRT had the lowest local recurrence rate (33%),
followed by PostOP chemotherapy (46%) and PostOP RT (48%), compared to surgery
alone (55%), with no significant overall survival difference. In 1986, their seven year
follow-up study concluded that PostOP CRT improved survival by 24% (/?=0.005),
compared to surgery alone (Douglas Jr., Moertel, & Mayer, 1986).
Even after the GITSG report, it was still questionable whether or not PostOP
CRT was more effective in improving local recurrence rates and overall survival than
PostOP RT alone, and a randomized clinical trial for T3, T4, or N1-2 RC assessed fiveyear recurrence rate and overall death rate between PostOP CRT versus PostOP RT alone
(Engstrom, et al, 2010). The estimated five-year recurrence rate for PostOP CRT was
41.5% (p=0.0016), compared to PostOP RT alone (62.7%), with a 29% decrease in the
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overall death rate. Thus, in 1990 the United States National Institutes of Health
Consensus Conference and the German Cancer Society Consensus Conference
(Junginger, Hossfeld, Sauer, & Hermanek, 1999) recommended the use of PostOP CRT
for Stage II and III RC.
2. Neoadjuvant (Preoperative) Therapy
In the last 20 years, several European trial groups (Camma et ah, 2000;
Peeters et al., 2007; Swedish Rectal Cancer Trial, 1997; van Gijn et ah, 201 l)have also
reported that a short-course of preoperative radiation therapy (PreOP RT) significantly
reduced local recurrence and improved overall survival compared to surgery alone. For
example, in early 1997, the Swedish rectal cancer trial (Swedish Rectal Cancer Trial,
1997) found that short-course PreOP RT (25 grey in five fractions in one week) reduced
local recurrence and improved overall survival for RC among patients with resectable
tumors compared to surgery alone. In 2005, their follow-up study (Birgisson, Pahlman,
Gunnarsson, & Glimelius, 2005) reported that a short-course PreOP RT for resectable RC
increased relative risk for PostOP hospitalization for subsequent bowel complications
compared to surgery alone. A Dutch colorectal cancer group (Peeters et al., 2007; van
Gijn et al., 2011) reported that short-course PreOP RT significantly improved 10-year
survival, compared to surgery alone, among stage III RC patients showing negative
resection margins (50% versus 40%,/?=0.032). Some randomized trials reported no local
recurrence and overall survival difference between short-course CRT (mainly preferred
by European countries) and long-course RT (U.S. preference) (Bujko et al., 2006; Ngan
et al., 2010).
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Advantages of PreOP over PostOP RT include: (1) Reduced tumor volume,
thereby enhancing preservation of anal sphincter and avoiding stoma (Sauer, Becker, &
Hohengerger, 2004; Sauer et ah, 2001; Wagman, Minsky, Cohen, Guillem, & Paty,
1998); (2) Avoidance of PostOP complications by substituting lateral lymph node
dissection with PreOP RT (Cancer Support Information Center, 2004); (3) Better
vascularization (oxygenation) of unaffected tissue before surgery yields superior RT
response (Cancer Support Information Center, 2004; Kachnic, 2006; Sauer et ah, 2004;
Sauer et ah, 2001; Wagman et ah, 1998); and (4) Reduced radiation-induced injury from
misplacement of the small bowel into the pelvis by surgical adhesions (Cancer Support
Information center, 2004; Kachnic, 2006; Sauer et ah, 2001; Wagman et ah, 1998).
In contrast, significant disadvantage of PreOP RT include: (1) Delay of surgery
by about 2 months (Cancer Support Information Center, 2004); (2) Surgical challenge
because of tissue adhesion caused by RT (Cancer Support Information Center, 2004);
(3) Increased probability of PostOP complications (he., infection) due to extended
healing time of surgical scar (Cancer Support Information Center, 2004); and (4) The
possibility of over-treating early-stage tumors, which otherwise would not have required
adjuvant RT (Madoff, 2004; Sauer, Becker & Hohengerger, 2004).
In addition to comparing PreOP RT versus surgery alone, several studies have
reported the effect of PreOP RT versus PostOP CRT and PreOP CRT versus PostOP
CRT. The United Kingdom and Canada randomized trial group (Sebag-Montefiore et al
2009; Stephens et ah, 2010) found that short-course PreOP RT reduced local recurrence
for RC, but did not improve overall survival, compared to PostOP CRT. In late 2004, a
German rectal cancer study group (Sauer, Becker, & Hohengerger, 2004) reported that
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PreOP CRT for stage II and III RC significantly reduced local recurrence (6% vs. 13%;
/?=0.006) and treatment-associated toxicity (27% vs. 40%; /?=0.001) compared with
PostOP CRT, although no difference was seen in overall survival. In April 2012, the 11
year follow-up of their study (Sauer et al., 2012) reported the unchanged conclusion from
their first report: PreOP CRT for stage II and III RC significantly reduced local
recurrence compared to PostOP CRT (7.1% vs. 10.1%; /?=0.048). However, there was no
effect on overall survival. An additional benefit of concurrent chemotherapy with RT is
amplification of the tumoricidal effect (Bosset et al., 2005) and reduction of distant
micrometastases (Ceelen, Van Nieuwenhove, & Fierens, 2009; Gerard et al., 2006; Sauer,
Becker, & Hohengerger, 2004).
3. Additional Postoperative Chemotherapy After Preoperative
Ch emoradioth erapy
Current National Comprehensive Cancer Network (NCCN) guidelines
(National Comprehensive Cancer Network, 2012) recommend a series of multimodality
therapies which consist of preoperative radiation therapy (PreOP RT) (45-50 grey in 2529 fractions) with concurrent chemotherapy, transabdominal resection, and postoperative
(PostOP) chemotherapy within six months for stage II (T3-4, NO, M0) and III (Any T,
Nl-2, M0) RC (American Joint Committee on Cancer, 2002). NCCN guidelines
(National Comprehensive Cancer Network, 2012) further recommend transabdominal
resection and PostOP CRT only, as an alternative among patients having medical
contraindications.
Current NCCN guidelines for stage II and III RC made reference to the adjuvant
chemotherapy trials for stage II or III colon cancer; fluorouracil plus leucovorin with the
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addition of oxaliplatin (FOLFOX4) as the standard adjuvant treatment (Andre et al.,
2009), and capecitabine plus oxaliplatin (XELOX) as additional adjuvant therapy (Haller
et al., 2011). Thus, there have been no evidence-based studies for stage II and III RC that
show the effect of adjuvant (PostOP) chemotherapy after neoadjuvant (PreOP) CRT and
surgical resection along with current NCCN guidelines (Yorio, Bhadkamkar, Kee, &
Garrett, 2012).
E. Future Modality Approaches for Stage II and III Rectal Cancer
Future approaches of optimal treatment for RC will depend on dose and duration
of PreOP RT, the combination of drugs, and treatment schedule. Recently, a four-stage
modality approach (PreOP chemotherapy, CRT, surgery, and PostOP chemotherapy) has
demonstrated that capecitabine/oxaliplatin (CAPOX) with cetuximub (i.e., monoclonal
anti-epidermal growth factor [EGFR] therapy) as PreOP chemotherapy showed higher
radiologic response and better overall survival than CAPOX alone (Dewdney et al.,
2012). A study testing the effects of duration difference for PreOP chemotherapy versus
PreOP CRT alone, PreOP CRT with two cycles of FOLFOX, and PreOP CRT with four
cycles of FOLFOX found that more PreOP FOLFOX was associated with higher
pathologic complete response rates with the same surgical complication rates (GarciaAguilar, Marcet, & Coutsoftides, 2011).
F. Association Between Demographic Variables and Multimodality Treatment
1. Age
Studies using Surveillance, Epidemiology, and End Results (SEER)
Program data reported that elderly patients were less likely to receive a radical surgery
and adjuvant therapy for RC (Chang, Skibber, Feig, & Rodriguez-Bigas, 2007; Schrag
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et al., 2001). A study using the National Cancer Data Base also reported that younger
patients were more likely to receive a surgical resection and adjuvant therapy even after
adjusting for comorbidities (Esnaola, Stewart, Feig, Skibber, & Rodriguez-Bigas, 2008).
2. Gender
The incidence of RC is higher among males than females (California
Cancer Facts & Figures, 2012; Siegel, Naishadham, & Jemal, 2012). According to Zutshi
et al. (2012), males were more likely to receive preoperative radiation therapy
(PreOP RT), even without significant differences in nodal or stage status compared to
females (93% vs. 82%, p=0.002), and females were more likely to receive postoperative
(PostOP) chemotherapy compared to males (39% vs. 20%,p=0.019). Other studies have
found that female patients were less likely to receive any RT (including PreOP RT) for
locally advanced RC (Baxter, Rothenberger, Morris, & Bullard, 2005; Mak et al., 2011).
Part of the gender difference in treatment modalities may be due to the anatomical
differences between females and males. Generally speaking, males have a more narrow
pelvis than females. Study findings indicate that a bulky tumor in the narrow male pelvis
is harder for surgeons to remove because it is surrounded by structures such as blood
vessels and organs, and instead of using medical instruments such as a stapler in males.
surgeons will predominantly perform hand-sewn or straight anastomosis (23.9%),
compared to females (10.8%) (/?=0.018) (Zutshi, Hull, Shedda, Lavery, & Hammel,
2012).
3. Race and Ethnicity
Studies indicate that health disparities exist between race/ethnic groups
that modify RC treatment modalities and thus survival (Morris, Billingsley, Baxter, &
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Baldwin, 2004; Sankaranarayanan et al., 2010). Findings support the hypothesis that
there are racial disparities in the treatment of gastrointestinal cancers, although most
reports have been limited to comparison between non-Hispanic blacks (NHBs) and nonHispanic whites (NHWs) (Morris, Billingsley, Baxter, & Baldwin, 2004; Morris, Wei,
Birkmeyer, & Birkmeyer, 2006; Polite, Dignam, & Olopade, 2005). For example, a study
group using the SEER Program data reported that African Americans patients with
resectable RC were less likely to receive surgical resection with sphincter preservation
and adjuvant RT compared to NHWs (Morris, Billingsley, Baxter, & Baldwin, 2004).
A recent study on RC using Los Angeles County Cancer Surveillance Program
data (1988-2006) among four race/ethnic groups (Asians, Hispanics, NHBs, and NHWs)
reported that Hispanic patients had highest percentage of young patients (22 %, <50 years
of age), of immigrants (84%), and had the second highest percentage of patients in the
lowest socioeconomic status (SES) (39%). Hispanic RC patients were more likely to
receive RT (44%) and chemotherapy (49%), compared to NHB patients who were most
likely to have distant metastasis (21%), least likely to receive radical surgery (75%), and
had the highest proportion of patients in the lowest SES category (32%) (Kim, J. et al.,
2011). Martinez, Chen, & Bilchik (2006) also found that Hispanics were significantly
more likely to receive PreOP RT and were less likely to receive sphincter-preserving
surgery than NHWs, even when adjusting for nodal status, tumor size, and T stage (1-4).
At the time of diagnosis, Hispanics are more likely to present with more bulky and
invasive tumors, and they may therefore need more aggressive treatment such as CRT,
even at the same histopathologic stage as other race/ethnic groups.
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According to our earlier findings, Hispanics are at higher risk of being diagnosed
with stage II-IV colorectal cancer (CRC) compared to NHWs (Morgan et ah, 2011).
Since Hispanics have the lowest incidence of RC among all race/ethnic groups in
California (Howlader et ah, 2011), their later stage at diagnosis may indicate that RC
among Hispanics is diagnosed late because access to healthcare is sub-optimal. The
National Healthcare Disparities Report 2011 (U.S. Department of Health and Human
Services, 2012) also indicated that Hispanics had worse quality health care and less
access to health care than NHWs. These disparities may, at least partly, be explained by
lack of communication skills caused by language barriers, and by lack of access to health
care, including insurance and transportation problems (Martinez, Chen, & Bilchik, 2006).
Kim, J. et ah (2011) found that Asians had the highest overall RC survival among
patients who received PreOP and PostOP CRT, followed by Hispanics, NHWs, and
NHBs (7.7 versus 5.7, 5.5, and 3.4 years, respectively;/?<0.001). Another study reported
that Asians, Hispanics, and NHWs with RC had significantly better survival in
multivariate analysis among patients who received PreOP RT compared to NHBs
(£>=0.001) (Lee et ah, 2012).
4. Socioeconomic Status
Socioeconomic status (SES) has a great impact on life expectancy and
mortality (Kim, J. M., 2012). According to the American Cancer Society, cancer
mortality decreases as SES increases (Freeman, 1989). RC incidence rate ratio was 4%
increased among low-income groups in Denmark (Egeberg, Halkjaer, Rottman, Hansen,
& Holten, 2008), and was decreased among high-income groups in Canada and the
United States (Boyd, Zhang-Salomons, Groome, & Mackillop, 1999; Mackillop, Zhang-
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Salomons, Boyd, & Groome, 2000). Socioeconomic and cultural factors are associated
with risk factors such as smoking and diet, and with outcomes like cancer (Nelson, 2003).
Cancer screening and treatment are affected by health insurance status which is strongly
associated with SES (Kim, J. M. et al., 2012).
Outcomes in race/ethnic groups will be modified when SES is included in the
model, and race/ethnicity and SES may have a complex interaction (Krieger, Chen,
Waterman, Rehkopf, & Subramanian, 2005). Thus, SES is a confounder of treatment
outcomes that are directly dependent on access to health care (Doubeni et al., 2007;
Harris et al., 2009; Le, Ziogas, Lipkin, & Zell, 2008).
G. Conclusion
According to literature review, it may be difficult for stage II and III RC patients
in California to receive treatment as same as current NCCN guidelines because treatment
may be given differently depending on age, gender, race/ethnicity, and SES. While it is
reasonable to assume that the outcome improvements which were reported by the
European trial groups have prompted changes in multimodality therapy of stage II and III
RC from adjuvant (postoperative, PostOP) to neoadjuvant (preoperative, PreOP) therapy,
survival benefits of these changes have not been adequately tested in a large-scale
population-based setting. This dissertation therefore has attempted to assess the
predictors (demographic variables) and the survival of stage II and III RC with various
multimodality treatments using the California Cancer Registry data from 1994 to 2009.
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CHAPTER 3
METHODS

A. Study Design
A non-concurrent cohort study design using the entire California population,
1994-2009, was used to assess demographic predictors and survival differences among
stage II and III rectal cancer (RC) patients receiving multimodality therapies such as
perioperative chemoradiation (PeriOP CRT) versus surgery alone, and preoperative
chemoradiation (PreOP CRT) versus postoperative chemoradiation (PostOP CRT),
adjusting for age, gender, race/ethnicity, and socioeconomic status. The statewide
California Cancer Registry (CCR) includes cancers diagnosed among the approximately
33.9 million residents, and has a rich demographic diversity (SEER Data, 2011).
B. Study Population
Of the 46,236 RC cases (not including rectosigmoid junction) diagnosed in
California during the 16 year study, 29,075 were unstaged, stage I or IV which were not
eligible for our study, and 17,161 were stage II and III. Among stage II and III RC, 2,029
did not receive radical surgery and were therefore also excluded. Among the remaining
15,132 patients receiving radical surgery, 2,988 received radical surgery only without
additional treatment (i.e. radiation therapy [RT] and/or chemotherapy), 8,852 received
PeriOP CRT which included radiation given before and/or after surgery with concurrent
chemotherapy, 4,280 patients received PreOP CRT, and 3,734 patients received PostOP
CRT. CCR data provide information on the sequence (time) of RT with surgery during
the first course of treatment such as PreOP RT, PostOP, and both, etc. while there is no
similar information for chemotherapy. However, CCR data specifies the date when
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chemotherapy was started. Therefore, to identify the time of chemotherapy given as first
course of treatment such as PreOP and PostOP, we estimated this based on the date of
first definitive surgery performed and the date when chemotherapy was started.
C. Data Analyses
Counts and percentages of PeriOP CRT versus surgery alone were assessed for
categories of age at diagnosis (<50, 50-74, and >75 years), gender, race/ethnicity
(Asian/Other [AO], Hispanic, non-Hispanic black [NHB], and non-Hispanic white
[NHW]), and for socioeconomic status (SES) quintiles (1-5 highest). PreOP CRT versus
PostOP CRT was also assessed for the same demographic variables as PeriOP CRT
versus surgery alone. However, temporal variables such as Early (1994-1997, same as
Swedish publication year), Middle (1998-2005, same as German publication year), and
Late (2006-2009) were also added. The SES index was computed using a principle
component analysis with seven census-derived economic and education variables
measured for the 21,960 Year 2000 Census block groups of residence at diagnosis in
California. Methods and variables used to compute the SES quintile index are described
by Yost et al. (Yost, Perkins, Cohen, Morris, & Wright, 2001) and did not include age.
sex, or race/ethnicity.
Using logistic regression, univariate odds ratios (OR) with 95% confidence
intervals (Cl) contrasting PeriOP CRT versus surgery alone and PreOP versus PostOP
CRT were computed for each of these independent variables. Additionally, a final
multivariable model was used where all independent variables were included. Interaction
between race/ethnicity and SES (race/ethnicityxSES) was assessed in the multivariable
model, however it was not significant (p>0.05).
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Cox proportional hazards regression was used to assess the risk of mortality
associated with PeriOP CRT versus surgery alone and PreOP CRT versus PostOP CRT
adjusting for other covariates, such as date of surgery (continuous variable), stage (II
and/or III), age (as categorical variable defined in logistic regression model), gender,
race/ethnicity, and SES. Due to non-linearity, a quadratic term for date of surgery ([date
of surgery]2), and interaction terms [(PeriOP CRT/surgery alone)x(date of surgery) and
(PeriOP CRT/surgery alone)x(date of surgery)2] were added to the full model. For all of
the independent variables, the proportional hazards (PH) assumption was evaluated using
log-log survival plots with time-interactions included in the full model. No serious
violations of the PH assumption were found. Statistical Analysis Software, version 9.3
(SAS, Cary, NC) was used for all analyses.
D. Limitations
Our data did not provide information on a second course of chemotherapy. We
have identified the type of chemotherapy given as first course of treatment, such as
single, multiple or not otherwise specified agents. Furthermore, we have no information
on which specific chemotherapies were used. This prevents assessment of the exact
NCCN treatment standard for stage II and III RC.
Although CCR data were not obtained in a randomized clinical trial, the data have
other strengths in that they represent a 100% sampling of eligible patients from a long
standing statewide population-based cancer registry with immense diversity. As such,
there is strong generalizability to the general population. However, our data provided no
information on comorbidities which could contribute to survival differences, and may
have also contributed to the choice of specific multimodality therapies. Our study
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included no mechanisms to balance for these unmeasured effects, which may have
differed in comparison groups.
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Abstract
Background: Prior to the mid-1980s, surgical resection was the only accepted treatment
of locally advanced rectal cancer (RC). More recently, chemoradiotherapy (CRT) before
and after surgery has been used as a multimodality therapy for stage II and III RC, to
reduce local and distant recurrence and to improve overall survival. Although several
study groups have prompted these changes, survival benefits of CRT have not been
adequately tested in a large-scale population-based setting.
Objective: To evaluate survival benefits of perioperative (PeriOP) CRT versus surgery
alone from 1994 through 2009 for stage II and III RC using the diverse California
population.
Design: A non-concurrent cohort study design of the entire California population, 19942009, was used to assess survival differences among RC patients receiving PeriOP CRT
versus surgery alone, adjusting for age, gender, race/ethnicity, and socioeconomic status.
Settings: The statewide California Cancer Registry.
Patients: Patients with stage II and III RC receiving only radical surgery (N=2,988) or
PeriOP CRT (N=8,852), among 46,236 RC cases.
Main Outcome Measures: Cox proportional hazards regression was used to assess the
risk of mortality associated with PeriOP CRT versus surgery alone adjusting for month of
surgery, stage, and selected demographic variables.
Results: In multivariable logistic regression, OR for receiving PeriOP CRT was higher
among Hispanic (OR=1.17, 1.01-1.34), compared to non-Hispanic whites. Cox
proportional hazards regression analysis showed that PeriOP CRT, relative to surgery
alone, was associated with lower mortality during the entire study period with survival
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benefit increasing overtime (1994-1997: HR^.73, 0.65-0.83; 1998-2001: HR-0.66,
0.60-0.73; 2002-2005: HR=0.55, 0.49-0.61; 2006-2009: HR=0.36, 0.31-0.43).
Limitations: Our data provided no information on comorbidities which could contribute
to treatment and survival differences.
Conclusions: Compared to patients treated with surgery alone, PeriOP CRT is associated
with significantly improved survival among stage II and III RC patients for the entire
study period.
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INTRODUCTION
Colorectal cancer (CRC) is currently the third leading cause of cancer deaths
among both females and males in the US with a five-year survival rate of 68% nationally1
and 66% in California.2 It is estimated that there will be 40,290 (16,790 females; 23,500
males) new rectal cancer (RC) diagnoses among Americans in 2012.1 An estimated 4,235
(1,785 females; 2,450 males) California residents will be diagnosed with RC during
2012, and approximately 935 (405 females; 535 males) will die from the disease.
Until the mid-1980’s, surgical resection without adjuvant therapy was the method
used for locally advanced RC.3 However, this single-modality treatment carried a high
risk for local recurrence with a propensity for spread. In 1985, the Gastrointestinal Tumor
Study Group (GITSG) reported that for stage II and III RC, adjuvant chemoradiotherapy
(CRT) resulted in lower local recurrence (33%) than surgery alone (55%).4 In 1986, their
seven-year follow-up study found that surgery combined with CRT improved survival by
24% (p=0.005), compared to surgery alone.5 The US National Institutes of Health
Consensus Conference (1990)6 and the German Cancer Society Consensus Conference
(1999)7 recommended the use of postoperative (PostOP) CRT for Stage II and III RC.
O

1 1

During the last 20 years, several European trial groups ’ have also reported that a
short-course of preoperative (PreOP) radiation therapy (RT) significantly reduced local
recurrence and improved overall survival for stage II and III RC, compared to surgery
alone. Specifically, the Swedish rectal cancer trial found that short-course PreOP RT (25
Gy delivered in five fractions in one week followed by surgery within one week) reduced
local recurrence and improved overall survival for RC among patients with resectable
tumors, compared to surgery alone. A Dutch colorectal cancer group 10,11 reported that
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short-course PreOP RT significantly improved 10-year survival, compared to surgery
alone, among stage III RC patients showing negative resection margins. In addition to
comparisons of PreOP RT versus surgery alone, several studies have reported the effect
of PreOP RT versus PostOP CRT and PreOP CRT versus PostOP CRT. The UK and
Canada randomized trial group 12,13 found that short-course PreOP RT reduced local
recurrence for RC, but did not improve overall survival, compared to PostOP CRT. A
German rectal cancer study group 14,15 reported that PreOP CRT for stage II and III RC
significantly reduced local recurrence compared with PostOP CRT, although no
difference was seen in overall survival. Current National Comprehensive Cancer
Network (NCCN) guidelines16 for stage II (T3-4, NO, MO) and III (Any T, Nl-2, MO)
RC17 recommend a sequence of treatment modalities such as PreOP CRT followed by
transabdominal resection and PostOP chemotherapy within 6 months.
While it is reasonable to assume that the outcome improvements reported by
European trial groups8"15 have prompted changes in multimodality therapy of stage II and
III RC, survival benefits of these changes have not been adequately tested in a large-scale
population-based setting. We sought to evaluate survival changes according to use of
perioperative (PreOP and/or PostOP) CRT versus surgery alone from 1994 through 2009
for stage II and III RC using the diverse California population.
MATERIALS AND METHODS
Study population : A non-concurrent cohort study design was used to assess
demographic predictors and outcomes of perioperative (PeriOP) CRT versus surgery
alone, for stage II and III

RC using the entire California population from 1994 through
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2009. The statewide California Cancer Registry (CCR) includes cancers diagnosed
•••18

among the approximately 33.9 million residents, and has a rich demographic diversity.
Of the 46,236 RC cases (not including recto-sigmoid junction) diagnosed in

California during the 16 year study, 17,161 were stage II and III, among which 2,029 did
not receive radical surgery and were ineligible for our study. The remaining 15,132
patients received radical surgery, with 3,292 excluded because they received RT or
chemotherapy only, either before or after surgery. Among the remaining 11,840 patients
that constitute our study population, 2,988 received radical surgery only without
additional treatment (i.e. RT and/or chemotherapy), while 8,852 received PeriOP CRT
which included RT given before and/or after surgery with concurrent chemotherapy
(Figure 4.1).
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Rectal cancer (RC) cases in California, 1994-2009 (N=46,236)

Stage I, IV, or unstaged RC (N=29,075) *-

Stage II & III RC (N=17,161)

Not received surgery,
or received local tumor excision,
or unknown for surgery
(N=2,029)

Received radical surgery (N=15,132)

yr

Received additional radiotherapy
or chemotherapy (N=3,292)

' r

Perioperative Chemoradiotherapy
(N=8,852)

Surgery alone
(N=2,988)

Figure 4.1. CONSORT diagram for patient’s selection in our study.
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Statistical Analyses: Counts and percentages (%) of surgery alone and PeriOP
CRT were assessed for categories of age at diagnosis (<50, 50-74, and >75 years),
gender, race/ethnicity (Asian/Other [AO], Hispanic, non-Hispanic black [NHB], and nonHispanic white [NHW]), and for socioeconomic status (SES) quintiles (1-5 highest). The
SES index was computed using a principle component analysis with seven censusderived economic and education variables measured for the 21,960 Year 2000 Census
block groups of residence at diagnosis in California. Methods and variables used to
compute the SES quintile index are described by Yost et al.19
Using logistic regression, univariate odds ratios with 95 % confidence intervals
(OR, Cl) for the use of PeriOP CRT versus surgery alone were computed for each of the
independent variables. The final multivariable model included all independent variables.
Interaction between race/ethnicity and SES (race/ethnicityxSES) was assessed in the
multivariable model, and it was not significant (/?=0.22) and therefore not included in the
final model.
Cox proportional hazards regression was used to assess risk of mortality
associated with PeriOP CRT versus surgery alone adjusting for other covariates,
including date of surgery, stage (II and/or III), age (as categorical variable defined in
logistic regression model), gender, race/ethnicity, and SES. Due to non-linearity of date
of surgery, we ran two models. In the first model we categorized this variable into four
time periods (1994-1997, 1998-2001, 2002-2005, and 2006-2009). In the second model
we used a quadratic term for date of surgery [(date of surgery)"]. Interaction terms
[(PeriOP CRT/surgery alone)x(date of surgery) and (PeriOP CRT/surgery alone)x(date
of surgery)2] were also included in the full model. For all of the independent variables,
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the proportional hazards (PH) assumption was evaluated using log-log survival plots with
time-interactions included in the full model. No serious violations of the PH assumption
were found. The Statistical Analysis Software (SAS), version 9.3^° was used for all
analyses.
RESULTS
Counts, proportions, univariate and adjusted ORs with 95% Cl for stage II and III
RC patients receiving PeriOP CRT versus surgery alone for demographic variables are
presented in Table 1. In univariate analyses, age was a determinant of PeriOP CRT with
decreasing use as age increased. Compared to the 50-74 age-category, the <50 age group
was more likely (OR=2.37, 1.98-2.84) to receive PeriOP CRT while the >75 age group
was less likely (OR=0.17, 0.15-0.18) to receive this treatment. Females were less likely to
receive PeriOP CRT (OR=0.68, 0.63-0.74) than males. AO and Hispanic patients were
19% and 35% more likely to receive PeriOP CRT, respectively, compared to NHW. ORs
for receiving PeriOP CRT increased monotonically from lowest (OR=0.65) to highest
SES (referent group).
The association between PeriOP CRT and demographic variables remained
virtually unchanged in the multivariable analysis, except for the association with
race/ethnicity. The higher odds of PeriOP CRT among the AOs was no longer present
(OR=0.98) and the finding for Hispanic ethnicity was attenuated, but still statistically
significant (OR=1.17) (Table 4.1).
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Table 4.1. Counts, proportions, univariate, and adjusted odds ratios (OR) with 95% confidence intervals (Cl) for Stage II and III rectal
cancer cases receiving perioperative chemoradiotherapy (PeriOP CRT) versus surgery alone by demographic variables, 1994-2009.
Data from the California Cancer Registry.__________________________________________________________________________
Independent
Variables

Counts'
(N=l 1,840)

%Surgery
alone

%PeriO
P CRT+

1,832

8.02%

91.98%

PeriOP CRT/Surgery alone

PeriOP CRT/Surgery alone
OR

95% Cl

Adjusted
OR*

2.37

1.98-2.84

2.41

0.15-0.18

0.17

95% Cl

2.01-2.89

Age
<50
50-74

7,071

17.13%

82.87%

1

>75

2,937

55.50%

44.50%

0.17

1
0.15-0.18
/?*<0.0001

Sex
0.63-0.74

0.76

0.69-0.83

Female

4,769

29.59%

70.41%

0.68

Male

7,071

22.30%

77.70%

1

1,565

23.13%

76.87%

1.19

1.05-1.35

0.98

0.85-1.13

1,895

21.00%

79.00%

1.35

1.19-1.52

1.17

1.01-1.34

598

29.43%

70.57%

0.86

0.72-1.03

0.83

0.67-1.02

7,782

26.37%

73.63%

1

Race/Ethnicity
Asian/Other
(AO)
Hispanic
Non-Hispanic
black (NHB)
Non-Hispanic
white (NHW)

1

I

Socioeconomic status (SES)#
1 Lowest

1,661

28.36%

71.64%

0.65

0.56-0.75

0.54

0.46-0.64

2

2.340

28.50%

71.50%

0.64

0.56-0.73

0.57

0.50-0.66

3

2,561

24.87%

75.13%

0.77

0.68-0.88

0.72

0.62-0.83

4

2,644

25.57%

74.43%

0.75

0.66-0.85

0.72

0.63-0.83

5 Highest

2,634

20.39%

79.61%

1

1
£>*<0.0001

'Counts of surgery alone and PeriOP CRT.
PeriOP CRT includes patients receiving radical surgery with preoperative and/or postoperative CRT.
* OR adjusting by demographic variables.
*£>-value for trend.
#SES is measured using a Census derived index based on place of residence [19],
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Multivariable survival analysis showed a time dependent association between
PeriOP CRT versus surgery alone. The hazard for all-cause mortality among those
receiving PeriOP CRT, compared to surgery alone, was reduced by 27% (HR=0.73, 0.650.83) for those treated during the 1994-1997 time period. This hazard continued to
decrease during later time periods, with a 64% reduction (HR^O.36, 0.31-0.43) for those
treated with PeriOP CRT between 2006 and 2009 (ptrend^.OOOl) (Table 4.2). When using
surgery date as a continuous variable in the Cox model (Figure 4.2), the time dependent
HR is even more apparent.

Table 4.2. Mortality hazard ratios (HR)f with 95% confidence interval (Ci) for
perioperative chemoradiotherapy (PeriOP CRT) versus surgery alone among stage II
and III rectal cancer cases over years of surgery date (four categories), 1994-2009.
Data from the California Cancer Registry.

HRf
0.73
0.66
0.55
0.36

Year of Surgery
1994-1997
1998-2001
2002-2005
2006-2009

95% CI
0.65-0.83
0.60-0.73
0.49-0.61
0.31-0.43
/> *<0.0001

+HR adjusted for age, gender, race/ethnicity, and socioeconomic status variables.
*p-value for trend.
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Figure 4.2. Mortality hazard ratios with 95% confidence interval for Perioperative
chemoradiotherapy versus surgery alone adjusted for demographic variables (age, gender,
race/ethnicity, and socioeconomic status) among stage II and III rectal cancer cases over
years of surgery date (continuous variable), 1994-2009.
Data from the California Cancer Registry
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DISCUSSION
Older patients (>75 years) with stage II and III RC were less likely to receive
PeriOP CRT during the study period, while patients younger than age 50 more frequently
received the adjuvant therapy. Older patients, especially those 80 years and older, may
have more co-morbidities, weaker immune system, and other medical contraindications
for CRT, while younger patients may be considered more hardy, with fewer co
morbidities, and therefore suitable for the more aggressive PeriOP CRT treatment.
Additionally, there may also be self-selection of limited treatment among the oldest study
subjects, some of whom may not believe they are able to handle the side effects of CRT,
or may have other reasons for not wanting the multimodality treatment.
We observed lower utilization of PeriOP CRT among females than males. The
explanation for this finding is unclear and should be explored further in studies with
cohort design where more information is available from surgery and pathology records as
well as imaging findings (CT, MRI, etc.). However, it is possible that RC in males tends
to have a more advanced presentation within the same histopathologic stage/category.
This could be due both to the fact that males may be more likely to delay seeking medical
care than females, and because a bulky tumor in the narrow male pelvis may be more
difficult to remove. 21
Our finding that the use of PeriOP CRT was significantly more common among
Hispanics, and tended to be less common among NHBs, compared to NHW patients, is in
line with a report from Martinez et al.

Even after adjustment for nodal status, tumor size

and T stage (1-4), Martinez et al. found that Hispanics were significantly more likely to
receive PreOP RT and were less likely to receive sphincter-preserving surgery than
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NHWs. Our findings may reflect different compliance with NCCN guidelines according
to race/ethnicity, and is supported by our earlier findings that Hispanics are at higher risk
of diagnosis with stage II-IV CRC, compared to NHWs23. Since Hispanics have the
lowest incidence of RC among all race/ethnic groups assessed in California24, their later
stage at diagnosis may indicate that RC among Hispanics is diagnosed at a more
advanced stage because access to healthcare in this ethnic group may be sub-optimal.
This supposition is supported by the National Healthcare Disparities Report 2011

which

shows that Hispanics tended to receive lower quality health care and have less access to
health care compared to NHWs. These disparities may, at least partly, be explained by
communication problems resulting from language barriers, and by lack of access to
insurance and transportation . Our findings are consistent with Martinez et al.

who

reported that Hispanics, compared to NHWs, are more likely to present with more bulky
and invasive tumors and may require more aggressive treatment such as CRT, even at the
same histopathologic stage.
Our analyses reveal significant differences across SES quintiles, indicating that
subjects in lower SES groups are less likely to receive PeriOP CRT, compared to those in
higher SES groups. Among stage II and III RC cases, SES is an independent selection
criterion for receiving PeriOP CRT as opposed to surgery alone. Our findings of a
survival benefit for PeriOP CRT versus surgery alone translates into a significantly
reduced survival for members of lower SES categories. Our observation of an association
between RC outcomes and SES are in line with a report by Kim et al., 26 who found that
the highest SES group had the best overall median survival (8.4 years) followed by the
middle (5.1 years) and lowest (3.8 years) group among residents of Los Angeles County.
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The time dependent improvement in survival among those receiving PeriOP CRT
is consistent with improved CRT methodology during the time period of our study. These
include improvements in medical technology such as advances in radiation techniques
(e.g. 3-dimentional conformal radiation therapy [3DCRT])27, intensity-modulated
radiation therapy (IMRT)27,28 and development of new drugs, particularly cetuximab

29,30

and bevacizumab31 which were added to fluorouracil (5-FU) and/or leucovorin (LV)
during the time period assessed.
Our data provided no direct information on comorbidities which could contribute
to survival differences. Although CCR data were not obtained in a randomized clinical
trial, our data have other strengths in that they represent a 100% sampling of eligible
patients from a long-standing statewide population-based cancer registry with immense
diversity. As such, there is strong generalizability to the general population. In
conclusion, PeriOP CRT reveals significantly improved survival among stage II and III
RC patients throughout the entire study period, compared to patients receiving surgery
alone. The survival benefit increased over the time-period of our study suggesting that
changes in CRT procedures have been modified over time.
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Abstract
Background: National Comprehensive Cancer Network guidelines recommend
preoperative (PreOP) chemoradiotherapy (CRT), transabdominal resection, and
postoperative (PostOP) chemotherapy for stage II and III rectal cancer (RC). European
trials evaluating the effect of PreOP versus PostOP CRT found no survival benefit.
However, the effect of a change from PostOP to PreOP CRT has not been evaluated in a
population-based setting.
Patients and Methods: We conducted a nonconcurrent cohort study evaluating
demographic predictors of multimodal therapy for stage II and III RC using the diverse
California Cancer registry population-based data. 4,280 patients received PreOP CRT and
3,734 patients receiving PostOP CRT. Cox proportional hazards regression was used to
assess survival over 192 months among PreOP and PostOP CRT patients, adjusting for
date of surgery, stage, age, gender, race/ethnicity, and socioeconomic status.
Results: Our findings showed a stepwise increase in the use of PreOP CRT across three
time-periods (1994-1997, 1998-2005, and 2006-2009) which was concomitant with
publication of findings from European trials. However, we did not find a clear survival
benefit for PreOP versus PostOP CRT.
Conclusions: Our study identified a clear shift in timing from PostOP to PreOP CRT.
However, we found no clear support for a survival benefit associated with this shift.
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INTRODUCTION
Colorectal cancer (CRC) is projected to be the second leading cause of cancer
death in the US during 2012, ranking number three among both females and males,
producing an estimated 51,690 deaths, nationwide. In the same year, it is estimated that
there will be 143,460 new CRC diagnoses among Americans, of which 40,290 are
expected to be rectal cancers [1]. In 2012, it is estimated that 4,235 rectal cancers will be
diagnosed among California residents, and that 935 persons with rectal cancer will die
[2]-

Rectal cancer originates within 12 cm proximal from the anal verge [3]. Risk of
recurrence of rectal cancer partly depends on tumor location relative to the anal verge [4].
Pelvic recurrence is more common for rectal than colon cancer [5-7], in part, because of
the proximity to pelvic structures, absence of serosa, and technical challenges
encountered in obtaining wide surgical margins. Current National Comprehensive Cancer
Network (NCCN) guidelines [8] recommend a series of multimodality therapies which
consist of preoperative (PreOP) radiation therapy (RT) (45-50 Gy in 25-29 fractions) with
concurrent chemotherapy, transabdominal resection, and postoperative (PostOP)
chemotherapy, within six months for stage II (T3-4, NO, M0) and III (Any T, Nl-2, M0)
rectal cancer [9]. NCCN guidelines [8] further recommend transabdominal resection and
PostOP chemoradiotherapy (CRT) only, as an alternative among patients having medical
contraindications.
Reports from the US National Institutes of Health Consensus Conference (1990)
[10] and the German Cancer Society Consensus Conference (1999) [11] recommended
use of PostOP CRT for Stage II and III rectal cancer. In early 1997, a report from the
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Swedish rectal cancer trial [12] found that short-term, high-dose PreOP RT (25 Gy in five
fractions in one week) reduced local recurrence and improved overall survival for rectal
cancer among patients with resectable tumors, compared to surgery alone. In late 2004,
the German rectal cancer study group [13] reported that PreOP CRT for Stage II and III
rectal cancer reduced local recurrence (6% vs. 13%; p=0.006) and treatment-associated
toxicity (27% vs. 40%; />=0.001), but did not improve overall survival, compared to
PostOP CRT.
Advantages of PreOP over PostOP RT include: (1) Reduced tumor volume.
thereby enhancing preservation of anal sphincter and avoiding stoma [13-15];
(2) Avoidance of PostOP complications by substituting PreOP RT for lateral lymph node
dissection [16]; (3) Better vascularization (oxygenation) of unaffected tissue before
surgery yields superior RT response [13-17]; and (4) Reduced radiation-induced injury
from misplacement of small bowel into the pelvis by surgical adhesions [14-17]. An
additional benefit of concurrent chemotherapy with RT is amplification of tumoricidal
effect [18] and reduction of distant micrometastases [13,19,20]. In contrast, a significant
disadvantage of PreOP RT is: (1) Delay of surgery by about two months [16];
(2) Surgical challenge for tissue adhesion caused by RT [16]; (3) Increased probability of
postoperative complications (i.e. infection) due to extended healing time of surgical scar
[16]; and (4) The possibility of over-treating early-stage tumors, which otherwise, would
not have required adjuvant RT [13,21].
In 2005, a follow-up study from the Swedish rectal cancer trial [22] reported that
a short-course PreOP RT for resectable rectal cancer increased relative risk for PostOP
hospitalization for subsequent bowel complications, compared to surgery alone. Recently,
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the Dutch colorectal cancer group [23] reported that short-course PreOP RT significantly
improved 10-year survival, compared to surgery alone, among stage III rectal cancer
patients showing negative resection margins [24]. A multicenter, randomized trial in the
UK and Canada [25,26] found that short-course PreOP RT alone, compared with PostOP
CRT, reduced local recurrence for rectal cancer, although no difference was seen in
overall survival. In April 2012, the German rectal cancer study group [27] reported the
11-year follow-up of their study. The conclusion was unchanged from their first follow
up report: PreOP CRT for stage II and III rectal cancer significantly reduced local
recurrence compared to PostOP CRT (7.1% vs. 10.1%; p=0.048), however, there was no
effect on overall survival.
While it is reasonable to assume that the outcome improvements which were
reported by the Swedish [12] and German trials [13] have prompted changes in
multimodality treatment of stage II and III rectal cancer, survival benefits of these
changes have not been adequately tested in a large-scale population-based setting. We
sought to evaluate treatment changes from PostOP to PreOP CRT practices and the effect
on overall survival from 1994 through 2009 among patients receiving radical operations
for stage II and III rectal cancer using the diverse California population.
PATIENTS AND METHODS
Study population : A non-concurrent cohort study design was used to evaluate
temporal and demographic predictors of multimodal therapy for stage II and III rectal
cancer using the entire California population for 1994-2009. The statewide California
Cancer Registry (CCR) includes approximately 31.5 million residents and rich
demographic diversity [28]. PreOP and PostOP chemotherapy timing (dependent
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variable) was computed based on dates of primary surgery and initial chemotherapy,
while RT was classified as PreOP or PostOP.
Of the 46,236 rectal cancer cases (not including rectosigmoid junction, RC)
diagnosed in California during the 16 year study, 29,075 were unstaged, stage I or IV
which were not eligible for our study, and 17,161 were stage II and III. Among stage II
and III RC, 2,029 did not receive radical surgery and were therefore also excluded. The
remaining 15,132 patients received radical surgery, and of these 5,364 did not receive
additional RT and/or chemotherapy, and for 1, 754 the timing for CRT was unknown
which render them ineligible for the study. Among the remaining 8,014 patients who
constitute our study populations, 4,280 patients received PreOP CRT and 3,734 patients
received PostOP CRT (Figure 5.1).
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Rectal cancer (RC) cases in California, 1994-2009 (N-46,236)

Stage I, IV, or unstaged (N=29,075) *

Stage II & III RC (N=17,161)

Not received surgery,
or received local tumor excision,
or unknown for surgery (N=2,029)

Received radical surgery (N=15,132)

Received no radiation, no chemotherapy,
both (i.e. surgery only),
or unknown sequence (N=5,364)
>

Received timing unknown
chemoradiotherapy (CRT)
(N=l,754)

Received either preoperative (PreOP) or postoperative (PostOP) CRT (N=8,014)

i

Received PostOP CRT (N=3,734)

Received PreOP CRT (N=4,280)

Figure 5.1. CONSORT diagram for patient’s selection in our study.
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Statistical Analyses: In the univariate analysis, counts and percentages (%) of
PreOP and PostOP CRT were assessed for three time periods at diagnosis: Early (19941997, same as Swedish publication year), Middle (1998-2005, same as German
publication year), and Late (2006-2009), for categories of age at diagnosis (<50, 50-74,
and 75+ years), gender, race/ethnicity (Asian/Other [AO], Hispanic, non-Hispanic black
[NHB], and non-Hispanic white [NHW]), and for socioeconomic status (SES) quintiles
(1-5 highest). The SES index was computed using a principle component analysis with
seven census-derived economic and education variables measured for the 21,960 Year
2000 Census block groups of residence at diagnosis in California. Methods and variables
used to compute the SES quintile index are described by Yost et al. [29] and did not
include age, sex, or race/ethnicity.
Univariate odds ratios with 95% confidence intervals (OR, Cl) contrasting PreOP
versus PostOP CRT were computed for each of these independent variables. The
association between PreOP versus PostOP CRT and independent variables (time-period
and demographic variables) was further evaluated using multivariable logistic regression.
Multiplicative interaction between race/ethnicity and SES (race/ethnicityxSES) was
assessed in the multivariable model, and it was not significant (/?=0.46).
In the multivariable survival analysis, Cox proportional hazards regression was
used to assess the risk of mortality associated with PreOP versus PostOP CRT adjusting
for other covariates, such as date of surgery (continuous variable), stage (II and III), age
(as categorical variable defined in logistic regression), gender, race/ethnicity, and SES.
2

Due to non-linearity, a quadratic term for date of surgery [(date of surgery)“] and
interaction terms [(PreOP/Post OP CRT)x(date of surgery) and (PreOP/Post OP

52

CRT)x(date of surgery)2], were added to the full model. For all of the independent
variables, the proportional hazards (PH) assumption was evaluated using log-log survival
plots and including time-interactions into the model. No serious violation of the PH
assumption was found. The Statistical Analysis Software (SAS), version 9.3 [30] was
used for all analyses.
RESULTS
Table 5.1 presents counts and proportions of stage II and III RC patients receiving
PreOP and PostOP CRT for three time-periods and demographic variables. Univariate
ORs with 95 percent Cl for PreOP versus PostOP CRT are also presented. The
proportions of PreOP CRT increased sequentially from Early to Late time-periods (Early:
OR=0.07, 0.06-0.08; Middle: OR^O.33, 0.29-0.37), compared to the latest time period.
Compared to the 50-74 age category, the younger age group was more likely to receive
PreOP CRT (OR=1.31, 1.17-1.47), while there was no difference for the older age group.
Females were less likely to receive PreOP CRT (0R=0.84, 0.77-0.92) than males, which
persisted when age was controlled for both as a continuous variable and with nine
different age categories. No significant difference was found in PreOP versus PostOP
CRT among race/ethnicity and SES groups, although the NHW and highest SES groups
tended to be somewhat more likely to have been treated with PreOP CRT.
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Table 5.1. Counts, proportions (%), and univariate odds ratios (OR) with 95% confidence intervals (Cl) for stage II and III rectal
cancer cases receiving perioperative chemoradiotherapy (CRT) by time-period and demographic variables, 1994-2009.
Data from the California Cancer Registry.

Variables

Counts of CRTS
(N=8,014)

% PreOP CRT+

% PostOP CRT1

OR

95% Cl

Time-Period
Early (1994-1997)

1,445

17.7%

82.4%

0.07

0.06-0.08

Middle (1998-2005)

4,038

51.7%

48.3%

0.33

0.29-0.37

Late (2006-2009)

2,531

76.6%

23.4%

1

<50

1,507

58.9%

41.1%

131

50-74

5,302

52.2%

47.8%

1

75+

1,205

52.0%

48.0%

1.00

0.88-1.13

Female

3,043

50.8%

49.2%

0.84

0.77-0.92

Male

4,971

55.0%

45.0%

1

Asian/Other (AO)

1,091

54.5%

45.6%

1.06

0.93-1.21

Hispanic

1,342

54.5%

45.5%

1.06

0.94-1.19

384

51.6%

48.4%

0.94

0.77-1.16

5,197

53.1%

47.0%

1

Age
1.17-1.47

Gender

Race/Ethnicity

Non-Hispanic black (NHB)
Non-Hispanic white (NHW)
Socioeconomic status (SES)*
1

1,069

52.1%

47.9%

0.87

0.75-1.01

2

1,501

52.0%

48.0%

0.86

0.75-0.99

3

1,746

53.4%

46.6%

0.91

0.80-1.04

4

1,788

53.0%

47.0%

0.87

0.79-1.02

55.7%

44.4%

1

5 Highest

1,910

s CRT includes patients receiving radical surgery with preoperative and postoperative chemoradiotherapy
tPreOP CRT includes patients receiving radical surgery with preoperative chemoradiotherapy.
‘PostOP CRT includes patients receiving radical surgery with postoperative chemoradiotherapy.
*SES is measured using a Census derived index based on place of residence [29].
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The association between PreOP CRT and time-periods remained virtually
unchanged in the multivariable analysis (p trend <0.0001) (Table 5.2). Likewise, the
associations with age (p trend <0.0001), gender, and SES (p trend

remained

consistent. However, compared to the univariate model, ORs for receiving PreOP versus
PostOP CRT were markedly lowered, although not statistically significant, among AO
and Hispanic patients in the multivariable model (AO: 0R=0.89, 0.77-1.03; Hispanic:
OR=0.92, 0.80-1.06).
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Table 5.2. Adjustec^odds ratios (OR) with 95 % confidence intervals (Cl) for stage II
and III rectal cancer cases receiving perioperative chemoradiotherapy (CRT) by timeperiod and demographic variables, 1994-2009.
Data from the California Cancer Registry.___________________________________
PreOP CRTVPostOP CRT*
Independent Variables
OR

95% Cl

Early (1994-1997)

0.07

0.06-0.08

Middle (1998-2005)

033

0.29-0.36

Time-Period

Late (2006-2009)

1
p*<0.0001

Age
<50
50-74
75+

1.15-1.48

131
1

0.83-1.09

0.95
p*<0.0001

Gender
Female
Male

0.75-0.92

0.83
1

Race/Ethnicity
Asian/Other (AO)

0.89

0.77-1.03

Hispanic

0.92

0.80-1.06

Non-Hispanic black (NHB)

0.98

0.78-1.23

Non-Hispanic white (NHW)

1

Socioeconomic status
(SES)#
0.74-1.04

1

0.88

2

0.86

0.74-1.00

3

0.86

0.74-0.99

4

0.87

0.76-1.01

5 Highest

1

P*=om
$Adjusted for time-period and demographic variables (age, gender, race/ethnicity, and
socioeconomic status).
+PreOP CRT includes patients receiving radical surgery with preoperative
chemoradiotherapy.
:PostOP chemoRT includes patients receiving radical surgery with postoperative
chemoradiotherapy.
*/?-value for trend.
#SES is measured using a Census derived index based on place
of residence [29].
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The Cox proportional hazards regression analysis showed that PreOP versus
PostOP CRT from 1994 through 2005 was associated with higher mortality (1994-1997:
HR-1.44, 1.20-1.71; 1998-2001: HR-1.35, 1.19-1.54; 2002-2005: HR-1.15, 0.99-1.34),
while mortality was lower from 2006 to 2009 (HR-0.81, 0.63-1.04) (Table 5.3,
Figure 5.2).

Table 5J. Hazard ratios (HR) with 95% confidence intervals (Cl) for
preoperative versus postoperative chemoradiotherapy among stage II and III
rectal cancer cases over years of surgery date (four categories), 1994-2009.
Data from the California Cancer Registry.

Year of Surgery
1994-1997
1998-2001
2002-2005
2006-2009

95% Cl
1.20-1.71
1.19-1.54
0.99-1.34
0.63-1.04

T

HR
1.44
1.35
1.15
0.81

p*<0.0001
+HR adjusted for age, gender, race/ethnicity, and socioeconomic status (SES)
variables.
*p-value for trend.
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Figure 5.2. Hazard ratios with 95% confidence interval for preoperative versus
postoperative chemoradiotheapy adjusted for demographic variables (age, gender,
race/ethnicity, and socioeconomic status) among stage II and III rectal cancer cases over
years of surgery date (continuous variable), 1994-2009.
Data from the California Cancer Registry.
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DISCUSSION
Our population-based findings provide direct evidence of a stepwise increase in
the ratio of PreOP to PostOP CRT over the three time-periods, Early (1990-1997),
Middle (1998-2005), and Late (2006-2009), among stage II and III RC patients in the
diverse California population consistent with current NCCN guidelines. This relatively
rapid shift was most likely propelled by findings from the European rectal cancer
treatment trials [12,13].
Younger age predicted more substantial shift from PostOP to PreOP CRT,
compared to age 50-74 years, while patients older than age 74 showed no change in
perioperative CRT during the study period. This difference may reflect a tendency for
more aggressive treatment of younger patients who may be hardier and experiencing
fewer co-morbidities than older patients who may have more medical contraindications to
treatment with PreOP CRT, particularly with regard to the immunosuppressive status of
those 80 years or older.
We observed a lower OR of PreOP to PostOP CRT among females than males.
The explanation for this is unclear. Since PreOP CRT reduces tumor sizes before surgery,
one possibility is that RC in males, even at the same histopathologic stage, are more often
adjacent to structures such as large blood vessels. The higher PreOP CRT may also
reflect later diagnosis and more serious presentation among males who in general are less
prone to seek medical assistance than females. This observed gender difference needs
further study in cohorts where more detailed information on surgery records, computed
tomography or magnetic resonance imaging is available.
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Our findings of lower ratios of PreOp to PostOp CRT among AO and Hispanic,
compared to NHW patients (Table 5.2), may reflect different compliance with NCCN
guidelines according to race/ethnic group. Although not significantly lower, these
findings may result from differences in hospital surgery services or quality of care
differences in various hospitals, including surgical volume and demographic
characteristics of populations served by various facilities. Hospitals with the best
treatment results for RC may have high surgical volume, be more likely to use the latest
treatment and methodology, be the first to follow new NCCN guidelines, and be located
in areas with mainly NHW populations. However, our analyses did not reveal any
significant differences in compliance with NCCN guidelines across SES quintiles,
indicating that SES does not by itself constitute a selection criterion for receiving PreOP
versus PostOP CRT among stage II and III RC patients.
According to our survival analysis, there is a significant difference in HR for
PreOP versus PostOP CRT depending on time of surgery (/?<0.0001) (Table 5.3 and
Figure 5.1). PreOP CRT is associated with higher mortality from 1994 to 2005, and with
lower mortality from 2006 to 2009. It is unlikely that this is related to the timing of CRT
(i.e. before or after surgery), because the outcome of this treatment modality is not
expected to be time dependent. Our findings are in line with the results from the German
randomized study [13,27] which found no difference in overall survival between PreOP
and PostOP CRT. The shift in survival over time from PostOP to PreOP CRT could
possibly be explained by factors associated with improvements in medical technology.
These include: (1) Advances in radiation techniques, such as 3-dimentional conformal
radiation therapy (3DCRT) [31], and intensity-modulated radiation therapy (IMRT)
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[31,32]; (2) Development of new drugs, such as cetuximab [33,34] approved by FDA in
2004, and bevacizumab [35] approved by FDA in 2004 as first line, in 2006 as second
line. Results from randomized clinical trials [33,34,35] indicate that survival in rectal
cancer patients has improved further after these new drugs were added to a standard
regimen of fluorouracil and/or leucovorin as PreOP CRT. Specifically, these new drugs
seem to improve survival by preventing distant metastasis. Increased use of PreOP versus
PostOP CRT after 2006 coincides with adoption of these new advances in both RT and
chemotherapy resulting in improved survival. Today, the main purpose of PreOP CRT is
to shrink the tumor size before surgery among stage II and III RC patients, and to reduce
complications during surgery and postoperatively, particularly if the tumor is located very
close to surrounding tissues. This may also have caused a selection bias in our study
population regarding which patients received PreOP versus PostOP CRT after 2006.
In conclusion, according to our findings, a stepwise change from PostOP to
PreOP CRT has taken a place in the treatment of stage II and III RC from 1994-2009.
Although our findings for 2008-2009 reveal significantly improved survival among
patients receiving PreOP versus PostOP CRT (Figure 5.2), this observation is most likely
due to other factors associated with the use of PreOP CRT. Those surgeons/hospitals
practicing PreOP CRT may be more likely to readily adopt newer radiation techniques
and use of newer chemotherapy, both of which have shown improved survival.
Limitations: Our data do not provide information on second course of
chemotherapy. We have identified the type of chemotherapy given as first course of
treatment, such as single, multiple or not otherwise specified agents. However, we have
no information about which specific drugs were used. This prevents assessment of the

61

exact NCCN treatment standard for stage II and III rectal cancer. Because short-course
RT is not an NCCN treatment standard, we did not assess this perioperative RT practice.
Although CCR data were not obtained in a randomized clinical trial, our data have other
strengths in that they represent a 100 percent sampling of eligible patients from a long
standing statewide population-based cancer registry with immense diversity. As such,
there is strong generalizability to the general population. However, our data provided no
information on comorbidities which could contribute to survival differences, and may
have also contributed to perioperative CRT timing. Our study included no mechanisms to
balance for these unmeasured effects, which may have differed in comparison groups.
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CHAPTER 6
CONCLUSION

Firstly, PeriOP CRT is associated with significantly improved survival among
stage II and III RC patients throughout the entire study period, 1994-2009, compared to
patients receiving surgery alone (Figure 4.2). The survival benefit increased over the
time-period of our study, suggesting that changes in CRT procedures have been modified
over time. These changes in CRT methodology include improvements in medical
technology such as advances in radiation techniques (e.g., 3-dimentional conformal
radiation therapy [3DCRT; Zutshi, Hull, Shedda, Lavery, & Hammel, 2012], and
intensity-modulated radiation therapy [IMRT; Pazdur, Wagman, Camphausen, &
Hoskins, 2009; Zutshi, Hull, Shedda, Lavery, & Hammel, 2012]) and development of
new drugs, particularly cetuximab (Galvin et ah, 2004; Jonker et ah, 2007) and
bevacizumab (Karapetis et ah, 2008) which were added to fluorouracil (5-FU) and/or
leucovorin (LV) during the time period assessed.
Secondly, a stepwise change from PostOP to PreOP CRT has taken a place in the
treatment of stage II and III RC from 1994-2009. Although our findings for 2008-2009
show a significantly improved survival among patients receiving PreOP versus PostOP
CRT (Figure 5.2), this observation is most likely due to other factors associated with the
use of PreOP CRT. Those surgeons/hospitals practicing PreOP CRT may be more likely
to readily adopt newer radiation techniques and use of newer chemotherapy, both of
which have shown improved survival.
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